GCPII_SYSTEM

"Design and development of novel reagents, tools, and techniques targeting human glutamate carboxypeptidases II and III"

Coordinatore	"BIOTECHNOLOGICKY USTAV - AV CR, V.V.I."    more  Organization address address: VIDENSKA 1083 city: PRAHA postcode: 142 20 contact info Titolo: Dr. Nome: Jan Cognome: Skoda Email: send email Telefono: -929 Fax: -929
Nazionalità Coordinatore	Czech Republic [CZ]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-RG
Funding Scheme	MC-IRG
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-11-01   -   2014-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	"BIOTECHNOLOGICKY USTAV - AV CR, V.V.I."  Organization address address: VIDENSKA 1083 city: PRAHA postcode: 142 20 contact info Titolo: Dr. Nome: Jan Cognome: Skoda Email: send email Telefono: -929 Fax: -929	CZ (PRAHA)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Glutamate carboxypeptidase II (GCPII) is a membrane-bound metallopeptidase with a vast pharmacological potential. Given the intimate involvement of the enzyme in neurotransmission under normal physiological conditions, it is not surprising that GCPII-specific inhibitors are neuroprotective in multiple preclinical models of neurodegeneration. Additionally, the cancer-associated form of GCPII is exploited as a target for immunotherapy/imaging of prostate cancer as well as neovasculature of solid tumors. Despite of its utilization in (pre)clinical settings, the physiological function of GCPII in the latter tissues is unknown and the whole picture is further complicated by the existence of GCPIII, a close GCPII homolog. The main goals of this proposal focus on the identification and development of novel reagents, tools and techniques associated with the GCPII/GCPIII system that may help addressing questions pertaining to the fundamental (patho)physiological roles of GCPII/GCPIII. We will use information from X-ray structures of GCPII/GCPIII complexes to modify and improve characteristics of small-molecule ligands currently used in experimental models of prostate cancer. Secondly, will develop an activity assay based on fluorescence polarization that, in turn, will be exploited for the identification of novel inhibitor scaffolds targeting GCPII/GCPIII. The physicochemical properties of the lead-like compounds will be further optimized to develop isoform (GCPII vs. GCPIII) specific reagents. Such compounds are not available at present and their availability is crucial for dissecting potentially diverse physiological functions of GCPIII and GCPII with implications for GCPII/III associated pathologies. Lastly, we will try to gain insight into non-enzymatic (receptor-like) properties of GCPII by identifying physiological interaction partner(s) of the enzyme using a tandem affinity purification approach.'

Introduzione (Teaser)

Scientists have found numerous ligands of a membrane-bound protein implicated in an unusual array of pathologies from neurotoxicity to prostate cancer. The ligands will help unravel diverse functions and develop targeted therapies.